(3E,5E,7E,9E)-1-(4-Hydroxy-phenyl)-4,8-dimethyl-10-(2,6,6-trimethyl-cyclohex-1-enyl)-deca-3,5,7,9-tetraen-2-one

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (3E,5E,7E,9E)-1-(4-Hydroxy-phenyl)-4,8-dimethyl-10-(2,6,6-trimethyl-cyclohex-1-enyl)-deca-3,5,7,9-tetraen-2-one
• 英文别名: (3E,5E,7E,9E)-1-(4-hydroxyphenyl)-4,8-dimethyl-10-(2,6,6-trimethylcyclohexen-1-yl)deca-3,5,7,9-tetraen-2-one
• 化学式: C₂₇H₃₄O₂
• 分子量: 390.566
• InChiKey: WKZPWMRGEOWZTC-PPBWNBFDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.7
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  视黄醛 在 TEA 、 四丁基氟化铵 、 水 、 sodium hexamethyldisilazane 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 (3E,5E,7E,9E)-1-(4-Hydroxy-phenyl)-4,8-dimethyl-10-(2,6,6-trimethyl-cyclohex-1-enyl)-deca-3,5,7,9-tetraen-2-one
  参考文献：
  名称：

  An unhydrolyzable analogue of N-(4-hydroxyphenyl)retinamide

  摘要：

  The synthesis of a nonhydrolyzable, carbon-linked analogue (4-HBR) of the retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) using Umpolung methods is described. Preliminary studies of biological activity show 4-HBR is similar to 4-HPR in its actions although a potentially relevant and desirable difference is its reduced suppression of plasma vitamin A levels. These results show that 4-HPR does not have to be hydrolyzed to retinoic acid to produce its chemotherapeutic effects. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00230-x

文献信息

• FENRETINIDE DERIVATIVES AND USES THEREOF AS THERAPEUTIC, DIAGNOSTIC AND IMAGING AGENTS
  申请人：Kalpana Ganjam V.

  公开号：US20110091383A1

  公开（公告）日：2011-04-21

  Synthetic peptidomimetic derivatives and phenyl group derivatives of Fenretinide (4-HPR) are disclosed, as are their uses as therapeutic, diagnostic and imaging agents for cancer and other diseases.

  本发明涉及Fenretinide（4-HPR）的合成肽类模拟衍生物和苯基衍生物，以及它们作为治疗、诊断和肿瘤及其他疾病成像剂的用途。
• Solid oral formulation of fenretinide
  申请人：LAURENT PHARMACEUTICALS

  公开号：US10406127B2

  公开（公告）日：2019-09-10

  Amorphous solid dispersions suitable for oral delivery comprising fenretinide or an analog thereof and at least one matrix polymer, and processes for making the dispersions, are disclosed. Also disclosed are solid oral formulations comprising the amorphous solid dispersions, as well as uses thereof for the prevention and/or treatment of diseases or conditions treatable by fenretinide, including but not limited to cancers, conditions associated with a lipid imbalance, cystic fibrosis, osteoporosis, conditions associated with inflammation or opportunistic infections, and other diseases such as diabetes, obesity, dry-form age-related macular degeneration.

  本发明公开了适用于口服给药的无定形固体分散体，该分散体包含芬瑞替尼或其类似物和至少一种基质聚合物，并公开了该分散体的制造工艺。还公开了包含无定形固体分散体的固体口服制剂，以及其用于预防和/或治疗可由芬雷肽治疗的疾病或病症的用途，包括但不限于癌症、与脂质失衡相关的病症、囊性纤维化、骨质疏松症、与炎症或机会性感染相关的病症，以及其他疾病，如糖尿病、肥胖症、干型老年性黄斑变性。
• TREATMENT OF NEURAL DISEASES OR CONDITIONS
  申请人：The Royal Institution for the Advancement of Learning/McGill University

  公开号：EP2244702A1

  公开（公告）日：2010-11-03
• SOLID ORAL FORMULATION OF FENRETINIDE
  申请人：Laurent Pharmaceuticals

  公开号：EP3171860A1

  公开（公告）日：2017-05-31
• COMPOSITIONS AND METHODS FOR ENHANCING ION TRANSPORTER ACTIVITY AND USES THEREOF
  申请人：The Royal Institution for the Advancement of Learning / McGill University

  公开号：EP3773619A1

  公开（公告）日：2021-02-17